- Home
- SBFG vs NKTX Comparison
SBFG vs NKTX Comparison
Compare SBFG & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFG
- NKTX
- Stock Information
- Founded
- SBFG 1983
- NKTX 2015
- Country
- SBFG United States
- NKTX United States
- Employees
- SBFG N/A
- NKTX N/A
- Industry
- SBFG Major Banks
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SBFG Finance
- NKTX Health Care
- Exchange
- SBFG Nasdaq
- NKTX Nasdaq
- Market Cap
- SBFG 126.1M
- NKTX 123.5M
- IPO Year
- SBFG N/A
- NKTX 2020
- Fundamental
- Price
- SBFG $19.65
- NKTX $2.08
- Analyst Decision
- SBFG
- NKTX Strong Buy
- Analyst Count
- SBFG 0
- NKTX 6
- Target Price
- SBFG N/A
- NKTX $14.40
- AVG Volume (30 Days)
- SBFG 68.2K
- NKTX 574.0K
- Earning Date
- SBFG 07-24-2025
- NKTX 08-12-2025
- Dividend Yield
- SBFG 3.02%
- NKTX N/A
- EPS Growth
- SBFG N/A
- NKTX N/A
- EPS
- SBFG 1.70
- NKTX N/A
- Revenue
- SBFG $58,813,000.00
- NKTX N/A
- Revenue This Year
- SBFG N/A
- NKTX N/A
- Revenue Next Year
- SBFG N/A
- NKTX N/A
- P/E Ratio
- SBFG $11.70
- NKTX N/A
- Revenue Growth
- SBFG 5.03
- NKTX N/A
- 52 Week Low
- SBFG $14.24
- NKTX $1.31
- 52 Week High
- SBFG $24.48
- NKTX $7.24
- Technical
- Relative Strength Index (RSI)
- SBFG 62.74
- NKTX 65.07
- Support Level
- SBFG $18.62
- NKTX $1.74
- Resistance Level
- SBFG $19.95
- NKTX $2.06
- Average True Range (ATR)
- SBFG 0.50
- NKTX 0.11
- MACD
- SBFG 0.09
- NKTX 0.03
- Stochastic Oscillator
- SBFG 95.49
- NKTX 95.24
About SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in single segment which is Banking.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.